Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vertex Pharmaceuticals
  6. Summary
    VRTX   US92532F1003

VERTEX PHARMACEUTICALS

(VRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/22/2021 11/23/2021 11/24/2021 11/26/2021 11/29/2021 Date
181.5(c) 186.85(c) 186.24(c) 183.59(c) 187.295 Last
1 173 920 2 159 574 3 086 841 1 127 378 545 369 Volume
-0.75% +2.95% -0.33% -1.42% +2.02% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 7 503 M - -
Net income 2021 2 287 M - -
Net cash position 2021 8 319 M - -
P/E ratio 2021 20,9x
Yield 2021 -
Sales 2022 8 218 M - -
Net income 2022 2 974 M - -
Net cash position 2022 12 088 M - -
P/E ratio 2022 16,0x
Yield 2022 -
Capitalization 46 678 M 46 678 M -
EV / Sales 2021 5,11x
EV / Sales 2022 4,21x
Nbr of Employees 3 400
Free-Float 99,8%
More Financials
Company
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination... 
Read more
More about the company
Ratings of Vertex Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about VERTEX PHARMACEUTICALS
11/22NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
11/22Vertex Announces Reimbursement Agreement in Spain for KAFTRIO (ivacaftor/tezacaftor/ele..
AQ
11/19Vertex Pharmaceuticals' Combination Therapy for Cystic Fibrosis Gets Spanish Approval f..
MT
11/19Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/el..
BU
11/19BMO Capital Starts Vertex Pharmaceuticals at Market Perform With $202 Price Target
MT
11/18Piper Sandler Downgrades Vertex Pharmaceuticals to Neutral From Overweight, Sets $218 P..
MT
11/18Novartis Said Considering Takeover in Biotech Sector
MT
11/12Vertex Pharmaceuticals Receives Positive Opinion on Cystic Fibrosis Treatment in Childr..
MT
11/12Vertex Cystic Fibrosis Treatment Gets CHMP Backing in Patients Ages 6-11
DJ
11/12Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) i..
BU
11/12Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for Kaftrio(Ivacafto..
CI
11/09Arbor Biotechnologies, Inc. announced that it has received $215 million in funding from..
CI
11/03VERTEX PHARMACEUTICALS INC / MA Management's Discussion and Analysis of Financial Cond..
AQ
11/03Tranche Update on Vertex Pharmaceuticals Incorporated's Equity Buyback Plan announced o..
CI
11/03Vertex Pharmaceuticals' Q3 Results Underline Competitive Position in Cystic Fibrosis, O..
MT
More news
News in other languages on VERTEX PHARMACEUTICALS
11/19La polythérapie de Vertex Pharmaceuticals contre la mucoviscidose est approuvée en Espa..
11/18Novartis envisagerait une reprise dans le secteur des biotechnologies
11/12Vertex Pharmaceuticals reçoit un avis favorable sur le traitement de la fibrose kystiqu..
11/11Tres valores para terminar el año
11/10Trois valeurs pour finir l’année
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Analysis
Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | MarketScreener
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 183,59 $
Average target price 254,30 $
Spread / Average Target 38,5%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS-22.32%46 678
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
BEIGENE, LTD.34.56%32 622